arrow
W

William P. Tew

Memorial Sloan Kettering Cancer Center
H指数:55
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer

卵巢癌中mirvetuximab soravtansine-gynx引起的白内障发生率及临床特征:一种未被充分认识的副作用

2026-04-250
PRE
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer

一项关于尼洛替尼与卵巢癌新诊断患者新辅助及术后化疗联合应用的试点研究

2025-10-310
PRE
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?

高级别浆液性卵巢癌在年龄组间的种系景观:年龄仅仅是一个数字吗?

2025-08-130
PRE
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

晚期卵巢癌患者接受抗FOLR1抗体药物偶联物治疗后的临床结局

2025-04-010
PRE
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study

接受或不接受化疗和非癌症对照的老年乳腺癌幸存者的功能下降: 来自Hurria老年患者 (HOPE) 前瞻性研究的结果

2024-04-282
PRE
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
2024-04-234
OAAI
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial
CANCER
IF5.1
2023-11-142
OAAI
Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
2023-10-013
PRE
Older Adult Oncology, Version 1.2021 Featured Updates to the NCCN Guidelines
2021-09-01107
OA
Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
2021-09-014
OAAI
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

老年人参与癌症临床试验: 障碍和干预措施的系统评价

2020-10-01281
OAAI